$7.52
2.31% yesterday
Nasdaq, Jul 21, 10:01 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$7.52
+0.12 1.62% 1M
-11.05 59.50% 6M
-11.65 60.77% YTD
-21.48 74.07% 1Y
-47.28 86.28% 3Y
-27.61 78.59% 5Y
-8.53 53.15% 10Y
-8.53 53.15% 20Y
Nasdaq, Closing price Mon, Jul 21 2025
+0.17 2.31%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Basic
Market capitalization
$536.5m
Enterprise Value
$-417.3m
Net debt
positive
Cash
$954.3m
Shares outstanding
73.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.9
EV/Sales
negative | negative
EV/FCF
1.7
P/B
0.8
Financial Health
Equity Ratio
51.5%
Return on Equity
-35.4%
ROCE
-12.2%
ROIC
78.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$426.9m | $283.4m
EBITDA
$-91.5m | $-117.9m
EBIT
$-95.6m | $-176.6m
Net Income
$-46.6m | $-111.4m
Free Cash Flow
$-252.8m
Growth (TTM | estimate)
Revenue
121.3% | 7.6%
EBITDA
85.4% | 52.0%
EBIT
84.9% | 29.4%
Net Income
91.8% | 44.0%
Free Cash Flow
29.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-21.4% | -41.6%
EBIT
-22.4%
Net
-10.9% | -39.3%
Free Cash Flow
-59.2%
More
EPS
$-0.7
FCF per Share
$-3.5
Short interest
11.6%
Employees
430
Rev per Employee
$610.0k
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Arvinas, Inc. forecast:

17x Buy
63%
10x Hold
37%

Analyst Opinions

27 Analysts have issued a Arvinas, Inc. forecast:

Buy
63%
Hold
37%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
427 427
121% 121%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 168 168
3% 3%
39%
- Research and Development Expense 355 355
46% 46%
83%
-92 -92
85% 85%
-21%
- Depreciation and Amortization 4.10 4.10
15% 15%
1%
EBIT (Operating Income) EBIT -96 -96
85% 85%
-22%
Net Profit -47 -47
92% 92%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn.
Neutral
GlobeNewsWire
about one month ago
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
Neutral
GlobeNewsWire
about 2 months ago
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today